A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

October 8, 2024

Study Completion Date

December 2, 2024

Conditions
Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Interventions
DRUG

Placebo

Placebo-matching capsules was administered orally.

DRUG

SPR720 500 mg

SPR720 500 mg (250 mg × 2 capsules) was administered orally.

DRUG

SPR720 1000 mg

SPR720 500 mg (250 mg × 4 capsules) was administered orally.

Trial Locations (28)

11042

Medical Facility, New Hyde Park

15213

Medical Facility, Pittsburgh

20007

Medical Facility, Washington D.C.

27103

Medical Facility, Winston-Salem

27599

Medical Facility, Chapel Hill

29425

Medical Facility, Charleston

30342

Medical facility, Atlanta

33136

Medical Facility, Miami

33470

Medical Facility, Loxahatchee Groves

33606

Medical Facility, Tampa

33870

Medical Facility, Sebring

35233

Medical Facility, Birmingham

44106

Medical Facility, Cleveland

52242

Medical Facility, Iowa City

55905

Medical Facility, Rochester

66103

Medical Facility, Kansas City

75020

Medical Facility, Denison

75090

Medical Facility, Sherman

75708

Medical Facility, Tyler

90033

Medical Facility, Los Angeles

91324

Medical Facility, Northridge

91355

Medical Facility, Santa Clarita

92663

Medical Facility, Newport Beach

93701

Medical Facility, Fresno

97239

Medical Facility, Portland

34746-4654

Medical Facility, Kissimmee

02740

Medical Facility, New Bedford

03756

Medical Facility, Lebanon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Spero Therapeutics

INDUSTRY

NCT05496374 - A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease | Biotech Hunter | Biotech Hunter